Current status of intravenous thrombolysis for acute ischemic stroke in Asia

International Journal of Stroke

Volumn 6, Issue 6, 2011, Pages 523-530

  Sharma, Vijay K ^a   Ng, Kay W P ^a   Venketasubramanian, Narayanaswamy ^a   Saqqur, Maher ^b   Teoh, Hock L ^a   Kaul, Subash ^c   Srivastava, Padma M V ^d   Sergentanis, Theodoris ^e   Suwanwela, Nijasri ^f   Nguyen, Thang H ^g   Lawrence Wong, K S ^h   Chan, Bernard P L ^a  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b UNIVERSITY OF ALBERTA   (Canada)

^c NIZAM'S INSTITUTE OF MEDICAL SCIENCES   (India)

^d ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^e UNIVERSITY OF ATHENS   (Greece)

^f CHULALONGKORN UNIVERSITY   (Thailand)

^g People's Hospital 115   (Viet Nam)

^h CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Acute ischemic stroke; Asia; Low dose IV tPA; Tissue plasminogen activator

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR;

ASIA; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ETHNIC DIFFERENCE; HUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

AGED; ASIA; BRAIN ISCHEMIA; CONFIDENCE INTERVALS; DATA INTERPRETATION, STATISTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHNIC GROUPS; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INJECTIONS, INTRAVENOUS; JAPAN; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; REGISTRIES; RISK ASSESSMENT; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 82255183792     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/j.1747-4949.2011.00671.x     Document Type: Review

References (47)

1. The National Institute of Disorders and Stroke rt-PA Stroke Study group: tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333:1581-7.
2. Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. Lancet 2008; 371:1612-23.
3. Reeves MJ, Arora S; Paul Coverdell Prototype Registries Writing Group et al. Acute stroke care in the US: results from 4 pilot prototypes of the Paul Coverdell National Acute Stroke Registry. Stroke 2005; 36:1232-40.
4. Nadeau JO, Shi S, on behalf of the Investigators for the Registry of the Canadian Stroke Network. et al. tPA use for stroke in the registry of the Canadian Stroke Network. Can J Neurol Sci 2005; 32:433-9.
5. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: global burden of disease study. Lancet 1997; 349:1269-76.
6. Bonita R, Mendis S, Truelsen T, Bogousslavsky J, Toole J, Yatsu F. The global stroke initiative. Lancet Neurol 2004; 3:391-3.
7. Huang P, Chen CH, Yang YH, Lin RT, Lin FC, Liu CK. Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: way to endeavor. Cerebrovasc Dis 2006; 22:423-8.
8. Suwanwela NC, Phanthumchinda K, Likitjaroen Y. Thrombolytic therapy in acute ischemic stroke in Asia: the first prospective evaluation. Clin Neurol Neurosurg 2006; 108:549-52.
9. Padma MV, Singh MB, Bhatia R. Hyperacute thrombolysis with IV rtPA of acute ischemic stroke: efficacy and safety profile of 54 patients at a tertiary referral center in a developing country. Neurol India 2007; 55:46-9.
10. Pandian JD, Sethi V, Dhillon R et al. Is intravenous thrombolysis feasible in a developing country? Cerebrovasc Dis 2005; 20:134-6.
11. Yamaguchi T; Japanese Thrombolysis Study Group. Intravenous tissue plasminogen activator in acute carotid artery territory stroke: a placebo controlled, double blind trial; in del Zoppe GJ, Mori E, Hacke W (eds): Thrombolytic Therapy in Acute Ischemic Stroke II. New York, NY: Springer Verlag, 1993: 59-65.
12. Sharma VK, Tsivgoulis G, Tan JH, Ong BKC, Chan BPL, Teoh HL. Feasibility and safety of intravenous thrombolysis in multiethnic Asian stroke patients in Singapore. J Stroke Cerebrovasc Dis 2010; 19:424-30.
13. Poungvarin N. Stroke in the developing world. Lancet 1998; 352 (Suppl. III): 19-22.
14. Wang Y, Wu D, Zhao X et al. Hospital resources for urokinase/recombinant tissue-type plasminogen activator therapy for acute stroke in Beijing. Surg Neurol 2009; 72:S2-7.
15. Ueshima S, Matsuo O. The differences in thrombolytic effects of administrated recombinant t-PA between Japanese and Caucasians. Thromb Haemost 2002; 87:544-6.
16. Yamaguchi T, Mori E; Japan Alteplase Clinical Trial (J-ACT) Group et al. Alteplase at 0·6mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke 2006; 37:1810-5.
17. Mori E, Minematsu K; for the J-ACT II Group et al. Effects of 0·6mg/kg intravenous alteplase on vascular and clinical outcomes in middle cerebral artery occlusion. Japan Alteplase Clinical Trial II (J-ACT II). Stroke 2010; 41:461-5.
18. Toyoda K, Koga M, Naganuma M et al. Routine use of intravenous low-dose recombinant tissue plasminogen activator in Japanese patients: general outcomes and prognostic factors from the SAMURAI Register. Stroke 2009; 40:3591-5.
19. Yoneda Y, Yamamoto S, Hara Y et al. Post-licensed 1-year experience of systemic thrombolysis with tissue plasminogen activator for ischemic stroke in a Japanese neuro-unit. Clin Neurol Neurosurg 2007; 109:567-70.
20. Nakagawara J, Minematsu K, Okada Y et al. Thrombolysis with 0·6mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: the Japan post-Marketing Alteplase Registration Study (J-MARS). Stroke 2010; 41:1984-9.
21. Wahlgren N, Ahmed N, Dávalos A et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke Monitoring Study (SITS-MOST): an observational study. Lancet 2007; 369:275-82.
22. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement: quality of reporting of meta-analyses. Lancet 1999; 354:1896-900.
23. Dean AG, Sullivan KM, Soe MM. OpenEpi: open source epidemiologic statistics for public health, version 2.3. Available at (Accessed 2 October 2010).
24. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21:1539-58.
25. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327:557-60.
26. Wasay M, Barohi H, Malik A, Yousuf A, Awan S, Kamal AK. Utilization and outcome of thrombolytic therapy for acute stroke in Pakistan. Neurol Sci 2010; 31:223-5.
27. Sharma SR, Sharma N. Hyperacute thrombolysis with recombinant tissue plasminogen activator of acute ischemic stroke: feasibility and effectivity from an Indian perspective. Ann Indian Acad Neurol 2008; 11:221-4.
28. Adams HP Jr, Bendixen BH, Kappelle LJ et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. Trial of Org 10172 in acute stroke treatment. Stroke 1993; 24:35-41.
29. Hsu YC, Sung SF, Ong CT, Wu CS, Su YH. Intravenous thrombolytic therapy for acute ischemic stroke: the experience of a community hospital. Acta Neurol Taiwan 2009; 18:14-20.
30. Lau AY, Soo YO, Graham CA et al. An expedited stroke triage pathway is the key to shortening the door-to-needle time in delivery of thrombolysis treatment. Hong Kong Med J 2010; 16:455-62.
31. Boddu DB, Prasad RG, Bandaru VCSS et al. Predictors of major neurologic improvement after intravenous thrombolysis in acute ischemic stroke: a hospital based study from Hyderabad, India. Ann Indian Acad Neurol 2010; 58:403-6.
32. Muengtaweepongsa S, Dharmasaroja P, Kummark U. Outcomes of intravenous thrombolytic therapy for acute ischemic stroke with an integrated acute stroke referral network: initial experience of a community-based hospital in a developing country. J Stroke Cerebrovasc Dis 2010 doi: DOI: 10.1016/j.jstrokecerebrovasdis.2010.03.017.
33. Adams HP Jr, del Zoppo G, Alberts MJ et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007; 38:1655-711.
34. Nguyen TH, Truong ATL, Ngo MB et al. Patients with thrombolysed stroke in Vietnam have an excellent outcome: results from the Vietnam Thrombolysis Registry. Eur J Neurol 2010; 17:1188-92.
35. Salam KA, Ummer K, Pradeep Kumar VG, Noone ML, Laila A, Ragini J. Intravenous thrombolysis for acute ischemic stroke: The Malabar experience 2003 to 2008. J Clin Neurosci 2009; 16:1276-8.
36. Zhou XY, Wanga SS, Collins ML, Davis SM, Yan B. Efficacy and safety of different doses of intravenous tissue plasminogen activator in Chinese patients with ischemic stroke. J Clin Neurosci 2010; 17:988-92.
37. Chao AC, Hsu HY, Chung CP et al. Outcomes of thrombolytic therapy for acute ischemic stroke in Chinese patients. The Taiwan Thrombolytic Therapy for Acute Ischemic Stroke (TTT-AIS) Study. Stroke 2010; 41:885-90.
38. Sacco R, Kargman DE, Quiong Gu, Zamanillo MC. Race-ethnicity and determinants of intracranial atherosclerotic cerebral infarction: the Northern Manhattan Stroke Study. Stroke 1995; 26:14-20.
39. Wong KS, Huang YN, Gao S, Lam WW, Chan YL, Kay R. Intracranial stenosis in Chinese patients with acute stroke. Neurology 1998; 50:812-3.
40. Gorelick PB, Caplan LR, Hier DB, Parker SL, Patel D. Racial differences in the distribution of anterior circulation occlusive disease. Neurology 1984; 34:54-9.
41. Feldmann E, Daneault N, Kwan E et al. Chinese-White differences in the distribution of occlusive cerebrovascular disease. Neurology 1990; 40:1541-5.
42. Kieffer SA, Takeya Y, Resch JA, Amplatz K. Racial differences in cerebrovascular disease: angiographic evaluation of Japanese and American populations. Am J Roentgenol 1967; 101:94-9.
43. Mori E, Yoneda Y, Tabuchi M et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 1992; 42:976-82.
44. Yamaguchi T, Hayakawa T, Kikuchi H; Japanese Thrombolysis Study Group. Intravenous tissue plasminogen activator ameliorates the outcome of hyperacute embolic stroke. Cerebrovasc Dis 1993; 3:269-72.
45. Yamaguchi T, Kikuchi H, Hayakawa T; Japanese Thrombolysis Study Group. Clinical efficacy and safety of intravenous tissue plasminogen activator in acute embolic stroke: a randomized, double-blind, dose comparison study of duteplase; in Yamaguchi T, Mori E, Minematsu K, del Zoppo GJ (eds): Thrombolytic Therapy in Acute Ischemic Stroke III. Tokyo, Japan: Springer-Verlag, 1995: 223-9.
46. Heuschmann PU, Berger K, Misselwitz B et al. Frequency of thrombolytic therapy in patients with acute ischemic stroke and the risk of in-hospital mortality: the German Stroke Registers Study Group. Stroke 2003; 34:1106-13.
47. Minematsu K, Yamaguchi T, Omae T. Spectacular shrinking deficit: rapid recovery from a major hemispheric syndrome by migration of an embolus. Neurology 1992; 42:157-62.